ARTELO BIOSCIENCES, INC. Proceeds from Sale and Maturity of Marketable Securities
ARTELO BIOSCIENCES, INC. (ARTL) reported Proceeds from Sale and Maturity of Marketable Securities of $0 for the 12-month period ending 2025-12-31, per its 8-K filed 2026-03-17.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2026-03-17
- ARTELO BIOSCIENCES, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ARTELO BIOSCIENCES, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- ARTELO BIOSCIENCES, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- ARTELO BIOSCIENCES, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- ARTELO BIOSCIENCES, INC. proceeds from sale and maturity of marketable securities for fiscal 2022 was $15.66M.
- ARTELO BIOSCIENCES, INC. proceeds from sale and maturity of marketable securities for fiscal 2021 was $2.66M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 4 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 8-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $0.00 8-K · filed 2026-03-17 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | $500.00K derived: sum of 4 quarters · filed 2026-03-17 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 8-K 3 month · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | $500.00K derived: sum of 3 quarters · filed 2026-03-17 | $4.75M derived: sum of 4 quarters · filed 2026-03-17 | |
| 2025-03-31 | $0.00 8-K · filed 2025-07-11 | $500.00K derived: sum of 2 quarters · filed 2026-03-17 | $4.75M derived: sum of 3 quarters · filed 2026-03-17 | $6.50M derived: sum of 4 quarters · filed 2026-03-17 | |
| 2024-12-31 | $500.00K derived: 8-K 12 month − 10-Q 9 month · filed 2026-03-17 | $4.75M derived: sum of 2 quarters · filed 2026-03-17 | $6.50M derived: sum of 3 quarters · filed 2026-03-17 | $8.25M 8-K · filed 2026-03-17 | |
| 2024-09-30 | $4.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $6.00M derived: sum of 2 quarters · filed 2025-11-12 | $7.75M 10-Q · filed 2025-11-12 | $11.44M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $1.75M derived: 10-Q 6 month − 8-K 3 month · filed 2025-08-13 | $3.50M 10-Q · filed 2025-08-13 | $7.19M derived: sum of 3 quarters · filed 2025-08-13 | $9.94M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $1.75M 8-K · filed 2025-07-11 | $5.44M derived: sum of 2 quarters · filed 2025-07-11 | $8.19M derived: sum of 3 quarters · filed 2025-07-11 | $10.94M derived: sum of 4 quarters · filed 2025-07-11 | |
| 2023-12-31 | $3.69M derived: 8-K 12 month − 10-Q 9 month · filed 2025-07-11 | $6.44M derived: sum of 2 quarters · filed 2025-07-11 | $9.19M derived: sum of 3 quarters · filed 2025-07-11 | $15.68M 8-K · filed 2025-07-11 | |
| 2023-09-30 | $2.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $5.50M derived: sum of 2 quarters · filed 2024-11-12 | $11.99M 10-Q · filed 2024-11-12 | $15.97M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $2.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $9.24M 10-Q · filed 2024-08-13 | $13.22M derived: sum of 3 quarters · filed 2024-08-13 | $17.47M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $6.49M 10-Q · filed 2024-05-13 | $10.47M derived: sum of 2 quarters · filed 2024-05-13 | $14.72M derived: sum of 3 quarters · filed 2024-05-13 | $19.44M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $3.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $8.23M derived: sum of 2 quarters · filed 2024-03-25 | $12.95M derived: sum of 3 quarters · filed 2024-03-25 | $15.66M 10-K · filed 2024-03-25 | |
| 2022-09-30 | $4.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $8.97M derived: sum of 2 quarters · filed 2023-11-13 | $11.68M 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $4.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $7.43M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $2.70M 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | $2.73M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $3.10M 10-Q · filed 2022-11-08 | ||||
| 2021-08-31 | $2.66M 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |